Ioflubenzamide I-131 - MedKoo Biosciences

Back to products

Browse products

Approved anticancer agents

Anticancer agents in trials

Anticancer agents in preclinical trials

Anticancer molecular libraries

Other drug agents

Drug intermediates

Bio-reagents and biochemicals

MedKoo product information:

Ioflubenzamide I-131

MedKoo Code#: 205496
Name: Ioflubenzamide I-131
CAS#: 864462-68-0 Synonym: code name: BA-100; MIP-1145; other name: Ioflubenzamide I-131. 131-I-MIP-1145; iodine I-131 MIP-1145; Chemical structure: (1). N-[2-(diethylamino)ethyl]-4-[(4-fluorobenzoyl)amino]-5-[131I]iodo-2-methoxybenzamide. (2) . Benzamide, N-[2-(diethylamino)ethyl]-4-[(4-fluorobenzoyl)amino]-5-iodo-2-methoxy-. trademark: Solazed®. 　 IUPAC/Chemical name: N-(4-((2-(diethylamino)ethyl)carbamoyl)-2-iodo (131-I)-5-methoxyphenyl)benzo[d][1,3]dioxole-5-carboxamide
Chemical structure	Theoretical analysis
	Chemical Formula: C22H26131IN3O5 Exact Mass: 543.09337 Molecular Weight: 543.36506 Elemental Analysis: C, 48.63; H, 4.82; I, 24.09; N, 7.73; O, 14.72
Availability and price: This agent is not in stock, may be available through custom synthesis. To inquire quotation and lead time or to ask questions, please send email to sales@medkoo.com to describe your needs. A representative will respond your email shortly. We offer big discount for orders of bulk quantities.

Information about this agent

Ioflubenzamide I-131 is an iodine 131-radiolabeled small-molecule benzamide compound with potential antineoplastic activity. The benzamide moiety of ioflubenzamide I-131 binds to melanin, selectively delivering a cyotoxic dose of gamma and beta radiation to melanin-expressing tumor cells. Melanin pigments, polymer derivatives of the amino acid tyrosine, are over-expressed in approximately 40% of melanomas. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).

Current developer: Molecular Insight Pharma

References

1: Joyal JL, Barrett JA, Marquis JC, Chen J, Hillier SM, Maresca KP, Boyd M, Gage K, Nimmagadda S, Kronauge JF, Friebe M, Dinkelborg L, Stubbs JB, Stabin MG, Mairs R, Pomper MG, Babich JW. Preclinical evaluation of an 131I-labeled benzamide for targeted radiotherapy of metastatic melanoma. Cancer Res. 2010 May 15;70(10):4045-53. Epub 2010 May 4. PubMed PMID: 20442292; PubMed Central PMCID: PMC2871064.

Contact MedKoo:

Email: sales@medkoo.com

(Keyword; CAS#; MedKoo code#)